文献速递重症综合管理与镇静镇痛心脑血管急症

体外膜氧合支持昏迷患者预后判断的连续脑电图标志物

Continuous Electroencephalography Markers of Prognostication in Comatose Patients on Extracorporeal Membrane Oxygenation.
PubMed 文献 · Neurocrit Care · 2022-04-11
一句话结论在标准化镇静停止方案下,ECMO昏迷患者cEEG保留反应性、存在状态变化和中等/良好变异性可能与出院存活相关。

本研究前瞻性收集2016年7月至2020年12月单中心接受ECMO支持的成人患者记录,在排除丙泊酚、氯胺酮或苯二氮䓬类等影响cEEG反应性的镇静药物后,对40例患者进行cEEG监测,评估频率、波幅、变异性、反应性和状态变化。结果显示,存活者中EEG反应性存在、状态变化存在和中等/良好变异性的比例显著高于死亡者,OR分别为无穷大、无穷大和13.57,P值分别为<0.001、<0.001和0.0299;出院存活灵敏度/特异度分别为100%/91.67%、100%/97.20%和75%/83.3%。作者认为,cEEG特征可能与ECMO昏迷患者出院存活相关,但需未来多中心更大样本研究验证。

要点

  • 在排除影响cEEG反应性的镇静药物(丙泊酚、氯胺酮、苯二氮䓬类)后,40例ECMO成人患者中存活者EEG反应性存在比例显著高于死亡者(OR无穷大,P<0.001)。
  • 存活者中EEG状态变化存在的比例显著高于死亡者(OR无穷大,P<0.001),出院存活灵敏度100%、特异度97.20%。
  • 存活者中中等/良好变异性的比例显著高于死亡者(OR 13.57,P=0.0299),出院存活灵敏度75%、特异度83.3%。
  • 27例在ECMO支持期间接受维持生命治疗撤除(WOLST),13例脱离ECMO,其中9例后续住院期间WOLST,4例出院存活;WOLST决策未受cEEG特征结果影响。
  • 作者认为cEEG特征(保留反应性、存在状态变化、中等/良好变异性)可能与出院存活相关,但未来需多中心更大样本研究验证。

适用人群与场景

  • 年龄≥18岁、于2016年7月至2020年12月在单中心开始ECMO支持的成人患者,前瞻性收集记录。
  • 根据纳入和排除标准进行cEEG监测;排除cEEG记录开始时使用影响cEEG反应性的镇静药物(丙泊酚、氯胺酮或苯二氮䓬类)者。
  • cEEG监测期间允许使用芬太尼和右美托咪定。

处置流程与药物剂量

  • 采用标准化镇静停止方案后行cEEG监测,评估频率、波幅、变异性、反应性和状态变化。
  • cEEG监测期间允许使用芬太尼和右美托咪定;记录开始时使用丙泊酚、氯胺酮或苯二氮䓬类者排除。

研究设计与关键结果

  • 前瞻性单中心研究,290例ECMO患者中40例在无混杂镇静情况下接受cEEG(中位年龄60岁,85%为静脉-动脉ECMO,15%为静脉-静脉ECMO)。
  • ECMO支持中位时长143小时,可分析cEEG中位时长24小时。
  • 27例在ECMO支持期间接受维持生命治疗撤除(WOLST);13例脱离ECMO,其中9例后续住院期间WOLST,4例出院存活。
  • WOLST决策未受cEEG特征结果影响。
  • 存活者与死亡者比较:EEG反应性存在比例更高(OR无穷大,P<0.001),状态变化存在比例更高(OR无穷大,P<0.001),中等/良好变异性比例更高(OR 13.57,P=0.0299)。
  • 出院存活灵敏度/特异度:保留反应性100%/91.67%,存在状态变化100%/97.20%,中等/良好变异性75%/83.3%。

证据类型、等级与局限

  • 证据类型:前瞻性单中心队列研究。
  • 局限:原文报告需未来多中心更大样本研究验证(future multicenter studies with larger patient cohorts are certainly warranted)。

对床旁实践的改变

  • 作者认为,ECMO昏迷患者cEEG显示保留反应性、存在状态变化和中等/良好变异性可能与出院存活相关。
  • 本研究验证了标准化镇静停止方案及无混杂镇静药物影响下进行cEEG分析的可行性;WOLST决策未受cEEG特征结果影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: We aimed to identify continuous electroencephalogram (cEEG) markers associated with survival and death in patients with extracorporeal membrane oxygenation (ECMO) support under standardized sedation cessation protocol.

METHODS: Prospectively collected records of adult patients (age ≥ 18 years) who were started on ECMO support in July 2016 to December 2020 at a single tertiary center were analyzed. cEEGs were performed on patients on the basis of inclusion and exclusion criteria. Patients receiving sedation that affect cEEG reactivity at the start of cEEG recording, including propofol, ketamine, or benzodiazepines, were excluded. We allowed fentanyl and dexmedetomidine during cEEG monitoring. cEEGs were evaluated for frequency, amplitude, variability, reactivity, and state changes.

RESULTS: Of 290 patients, 40 underwent cEEG in the absence of confounding sedation (median age 60 years, 85% venoarterial-ECMO, 15% venovenous-ECMO). The median length of ECMO support and analyzable cEEG were 143 h and 24 h, respectively. A total of 27 patients underwent withdrawal of life-sustaining therapies (WOLST) during ECMO support. Of the 13 who weaned off ECMO, 9 underwent WOLST later in the hospitalization and 4 survived at hospital discharge. Decisions of WOLST were not influenced by cEEG features' results. Proportions of present EEG reactivity, present state changes, and fair/good variability were significantly higher in patients who survived compared with those who died (odds ratios infinity, infinity, and 13.57, respectively; p values < 0.001, < 0.001, and 0.0299, respectively). Sensitivity and specificity for survival at discharge were 100% and 91.67% for intact reactivity, 100% and 97.20% for present state changes, and 75% and 83.3% for fair/good variability.

CONCLUSIONS: Although future multicenter studies with larger patient cohorts are certainly warranted, we were able to validate the feasibility of protocolized sedation cessation and cEEG analyses in the absence of a confounding effect from sedating medications. Moreover, we demonstrate some evidence that cEEG features of intact reactivity, present state changes, and fair/good variability in comatose patients on ECMO may be associated with survival at hospital discharge.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Hwang J, Bronder J, Martinez NC, et al. Continuous Electroencephalography Markers of Prognostication in Comatose Patients on Extracorporeal Membrane Oxygenation. Neurocrit Care. 2022. PMID: 35411539. doi:10.1007/s12028-022-01482-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。